Eziafa I Oduah

Journal Article Future Oncol · April 2026 Immunotherapy resistance represents a major unmet clinical need for patients with metastatic non-small cell lung cancer (NSCLC). Preclinical studies have identified PCSK9 as an immunosuppressive regulator of antigen presentation, providing a compelling rat ... Full text Link to item Cite

Data from Oncogenic Mutant p53 Sensitizes Non–Small Cell Lung Cancer Cells to Proteasome Inhibition via Oxidative Stress–Dependent Induction of Mitochondrial Apoptosis

Other · March 16, 2026 <div>AbstractNon–small cell lung cancer (NSCLC) cells with oncogenic mutant p53 (Onc-p53) alleles exhibit significantly higher levels of proteasome activity, indicating that Onc-p53 induces prote ... Full text Cite

Figure S4 from Oncogenic Mutant p53 Sensitizes Non–Small Cell Lung Cancer Cells to Proteasome Inhibition via Oxidative Stress–Dependent Induction of Mitochondrial Apoptosis

Other · March 16, 2026 Figure S4 ... Full text Cite

Figure S5 from Oncogenic Mutant p53 Sensitizes Non–Small Cell Lung Cancer Cells to Proteasome Inhibition via Oxidative Stress–Dependent Induction of Mitochondrial Apoptosis

Other · March 16, 2026 Figure S5 ... Full text Cite

Table S1 from Oncogenic Mutant p53 Sensitizes Non–Small Cell Lung Cancer Cells to Proteasome Inhibition via Oxidative Stress–Dependent Induction of Mitochondrial Apoptosis

Other · March 16, 2026 Table S1 ... Full text Cite

Figure S2 from Oncogenic Mutant p53 Sensitizes Non–Small Cell Lung Cancer Cells to Proteasome Inhibition via Oxidative Stress–Dependent Induction of Mitochondrial Apoptosis

Other · March 16, 2026 Figure S2 ... Full text Cite

Figure S1 from Oncogenic Mutant p53 Sensitizes Non–Small Cell Lung Cancer Cells to Proteasome Inhibition via Oxidative Stress–Dependent Induction of Mitochondrial Apoptosis

Other · March 16, 2026 Figure S1 ... Full text Cite

Figure S6 from Oncogenic Mutant p53 Sensitizes Non–Small Cell Lung Cancer Cells to Proteasome Inhibition via Oxidative Stress–Dependent Induction of Mitochondrial Apoptosis

Other · March 16, 2026 Figure S6 ... Full text Cite

Figure S3 from Oncogenic Mutant p53 Sensitizes Non–Small Cell Lung Cancer Cells to Proteasome Inhibition via Oxidative Stress–Dependent Induction of Mitochondrial Apoptosis

Other · March 16, 2026 Figure S3 ... Full text Cite

ICTIS: A Novel Scoring System to Assess the Inclusivity of Advanced NSCLC Immunotherapy Trials.

Journal Article JTO Clin Res Rep · November 2025 INTRODUCTION: Immunotherapy has revolutionized the treatment of NSCLC. However, trials that led to approval of these agents and ongoing trials often include overly included overly restrictive exclusion criteria, limiting access for a significant proportion ... Full text Link to item Cite

Perioperative pembrolizumab in early-stage non-small cell lung cancer (NSCLC): conventional and distribution-based immune profiling of the tumor microenvironment and peripheral circulation.

Journal Article J Immunother Cancer · October 31, 2025 PURPOSE: A recently published phase 2 neoadjuvant trial in patients with early-stage non-small cell lung cancer (NSCLC) (NCT02818920) evaluated the potential efficacy of pembrolizumab administration in the absence of chemotherapy. This communication report ... Full text Link to item Cite

A Phase 2 Study of PCSK9 Inhibitor, Alirocumab, and PD1 Inhibitor, Cemiplimab, in Advanced Immunorefractory Metastatic NSCLC

Conference JOURNAL OF THORACIC ONCOLOGY · October 2025 Link to item Cite

Neoadjuvant, Perioperative, and Adjuvant Immunotherapy in Early-Stage Surgically Resectable Non-Small Cell Lung Cancer: Updates and Future Perspectives.

Journal Article Cancers (Basel) · June 21, 2025 Historically, systemic therapy for resectable non-small cell lung cancer (NSCLC) has been associated with a modest impact on overall survival. The current treatment options for early-stage resectable NSCLC include neoadjuvant, adjuvant, and perioperative i ... Full text Link to item Cite

Safety, efficacy, and tumor immune microenvironment changes with neoadjuvant chemotherapy and cemiplimab with or without alirocumab in stage 1B-3A non-small cell lung cancer.

Conference Journal of Clinical Oncology · June 2025 TPS8118Background: The addition of immune checkpoint blockade to neoadjuvant and adjuvant therapy is now standard of care in ... Full text Cite

A Critical Review of Immunomodulation in the Management of Inoperable Stage III NSCLC.

Journal Article Cancers (Basel) · May 30, 2025 The current standard of care for inoperable stage III non-small cell lung cancer (NSCLC) is concurrent chemotherapy and radiation therapy with consolidation durvalumab. Despite this approach, about 50% of patients will experience disease recurrence, with a ... Full text Link to item Cite

Neoadjuvant, Perioperative, and Adjuvant Immunotherapy in Early-Stage Surgically Resectable Non-Small Cell Lung Cancer: Updates and Future Perspectives.

Preprint · May 5, 2025 Full text Cite

Table S1 from Oncogenic Mutant p53 Sensitizes Non–Small Cell Lung Cancer Cells to Proteasome Inhibition via Oxidative Stress–Dependent Induction of Mitochondrial Apoptosis

Other · April 3, 2025 Table S1 ... Full text Cite

Figure S3 from Oncogenic Mutant p53 Sensitizes Non–Small Cell Lung Cancer Cells to Proteasome Inhibition via Oxidative Stress–Dependent Induction of Mitochondrial Apoptosis

Other · April 3, 2025 Figure S3 ... Full text Cite

Figure 2 from Oncogenic Mutant p53 Sensitizes Non–Small Cell Lung Cancer Cells to Proteasome Inhibition via Oxidative Stress–Dependent Induction of Mitochondrial Apoptosis

Other · April 3, 2025 Onc-p53 NSCLC cells exhibit basal and PI-induced oxidative stress. A, Average oxidized (GSSG) vs. reduced (GSH) levels of GSH obtained from metabolomic profiles (DepMap) of NSCLC cell lines that either ... Full text Cite

Figure S1 from Oncogenic Mutant p53 Sensitizes Non–Small Cell Lung Cancer Cells to Proteasome Inhibition via Oxidative Stress–Dependent Induction of Mitochondrial Apoptosis

Other · April 3, 2025 Figure S1 ... Full text Cite

Figure S6 from Oncogenic Mutant p53 Sensitizes Non–Small Cell Lung Cancer Cells to Proteasome Inhibition via Oxidative Stress–Dependent Induction of Mitochondrial Apoptosis

Other · April 3, 2025 Figure S6 ... Full text Cite

Figure S5 from Oncogenic Mutant p53 Sensitizes Non–Small Cell Lung Cancer Cells to Proteasome Inhibition via Oxidative Stress–Dependent Induction of Mitochondrial Apoptosis

Other · April 3, 2025 Figure S5 ... Full text Cite

Figure S4 from Oncogenic Mutant p53 Sensitizes Non–Small Cell Lung Cancer Cells to Proteasome Inhibition via Oxidative Stress–Dependent Induction of Mitochondrial Apoptosis

Other · April 3, 2025 Figure S4 ... Full text Cite

Figure S2 from Oncogenic Mutant p53 Sensitizes Non–Small Cell Lung Cancer Cells to Proteasome Inhibition via Oxidative Stress–Dependent Induction of Mitochondrial Apoptosis

Other · April 3, 2025 Figure S2 ... Full text Cite

A single arm phase II study of PCSK9 inhibitor, alirocumab, and PD-1 inhibitor, cemiplimab, in advanced immuno-refractory metastatic non-small cell lung cancer (TOP2201)

Conference JOURNAL OF THORACIC ONCOLOGY · March 2025 Link to item Cite

Perioperative pembrolizumab in early-stage non-small cell lung cancer (NSCLC): safety, efficacy, and exploratory biomarker analysis.

Journal Article J Immunother Cancer · February 4, 2025 BACKGROUND: Our study was designed to determine the safety, efficacy, and immunological effects of perioperative pembrolizumab in early-stage NSCLC. METHODS: This is a single-arm phase II study of perioperative pembrolizumab in patients with untreated, cli ... Full text Link to item Cite

Sotorasib for the treatment of locally advanced/metastatic non-small cell lung cancer.

Journal Article Future Oncol · January 2025 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation is prognostic of poor survival for patients with non-small cell lung cancer (NSCLC). KRAS G12C mutations occur in 13% of NSCLC cases and despite the frequency of this mutation, advances in drug dev ... Full text Link to item Cite

Figure S5 from Oncogenic Mutant p53 Sensitizes Non–Small Cell Lung Cancer Cells to Proteasome Inhibition via Oxidative Stress–Dependent Induction of Mitochondrial Apoptosis

Other · October 15, 2024 Figure S5 ... Full text Cite

Figure 5 from Oncogenic Mutant p53 Sensitizes Non–Small Cell Lung Cancer Cells to Proteasome Inhibition via Oxidative Stress–Dependent Induction of Mitochondrial Apoptosis

Other · October 15, 2024 Navitoclax enhances BTZ-induced cytotoxicity. A and B, H1975 and H460 cells were treated with vehicle or the indicated concentrations of navitoclax with/without BTZ (2 nmol/L) for 96 hours. Cell viabil ... Full text Cite

Figure 4 from Oncogenic Mutant p53 Sensitizes Non–Small Cell Lung Cancer Cells to Proteasome Inhibition via Oxidative Stress–Dependent Induction of Mitochondrial Apoptosis

Other · October 15, 2024 The Onc-p53–NRF2–ATF3–NOXA pathway contributes to BTZ-induced apoptosis in Onc-p53 NSCLC cells. A, H1975 cells were treated with vehicle or BTZ (10 nmol/L) ± NAC (1 mmol/L) for 24 hours, and confocal i ... Full text Cite

Table 1 from Oncogenic Mutant p53 Sensitizes Non–Small Cell Lung Cancer Cells to Proteasome Inhibition via Oxidative Stress–Dependent Induction of Mitochondrial Apoptosis

Other · October 15, 2024 IC50 values for BTZ and CFZ in indicated NSCLC cell lines ... Full text Cite

Figure 1 from Oncogenic Mutant p53 Sensitizes Non–Small Cell Lung Cancer Cells to Proteasome Inhibition via Oxidative Stress–Dependent Induction of Mitochondrial Apoptosis

Other · October 15, 2024 Onc-p53 regulates basal levels of 20S proteasome activity and is required for BTZ-induced cytotoxicity in NSCLC cells. A, 20S proteasome activity was determined in the indicated cell lines using a fluorometric proteosome ... Full text Cite

Figure S1 from Oncogenic Mutant p53 Sensitizes Non–Small Cell Lung Cancer Cells to Proteasome Inhibition via Oxidative Stress–Dependent Induction of Mitochondrial Apoptosis

Other · October 15, 2024 Figure S1 ... Full text Cite

Table S1 from Oncogenic Mutant p53 Sensitizes Non–Small Cell Lung Cancer Cells to Proteasome Inhibition via Oxidative Stress–Dependent Induction of Mitochondrial Apoptosis

Other · October 15, 2024 Table S1 ... Full text Cite

Figure S2 from Oncogenic Mutant p53 Sensitizes Non–Small Cell Lung Cancer Cells to Proteasome Inhibition via Oxidative Stress–Dependent Induction of Mitochondrial Apoptosis

Other · October 15, 2024 Figure S2 ... Full text Cite

Figure S4 from Oncogenic Mutant p53 Sensitizes Non–Small Cell Lung Cancer Cells to Proteasome Inhibition via Oxidative Stress–Dependent Induction of Mitochondrial Apoptosis

Other · October 15, 2024 Figure S4 ... Full text Cite

Figure 3 from Oncogenic Mutant p53 Sensitizes Non–Small Cell Lung Cancer Cells to Proteasome Inhibition via Oxidative Stress–Dependent Induction of Mitochondrial Apoptosis

Other · October 15, 2024 BTZ induces ATF3/NOXA and caspase-dependent apoptosis. A, H1975 cells were pretreated (30 minutes) with vehicle or the pan-caspase inhibitor QVD-OPh (QVD; 1 µmol/L) and then treated with vehicle or BTZ (5 nmol/L) for 48 ... Full text Cite

Figure S3 from Oncogenic Mutant p53 Sensitizes Non–Small Cell Lung Cancer Cells to Proteasome Inhibition via Oxidative Stress–Dependent Induction of Mitochondrial Apoptosis

Other · October 15, 2024 Figure S3 ... Full text Cite

Figure S6 from Oncogenic Mutant p53 Sensitizes Non–Small Cell Lung Cancer Cells to Proteasome Inhibition via Oxidative Stress–Dependent Induction of Mitochondrial Apoptosis

Other · October 15, 2024 Figure S6 ... Full text Cite

Oncogenic Mutant p53 Sensitizes Non-Small Cell Lung Cancer Cells to Proteasome Inhibition via Oxidative Stress-Dependent Induction of Mitochondrial Apoptosis.

Journal Article Cancer Res Commun · October 1, 2024 NSCLC is the leading cause of cancer death due, in part, to a lack of active therapies in advanced disease. We demonstrate that combination therapy with a proteasome inhibitor, BH3-mimetic, and chemotherapy is an active precision therapy in NSCLC cells and ... Full text Link to item Cite

Proteasome inhibition paradoxically degrades gain-of-function mutant p53 R273H in NSCLC and could have therapeutic implications.

Journal Article Front Oncol · 2024 Lung cancer is the leading cause of cancer mortality. Despite therapeutic advances in recent years, new treatment strategies are needed to improve outcomes of lung cancer patients. Mutant p53 is prevalent in lung cancers and drives several hallmarks of can ... Full text Link to item Cite

The emerging landscape of EFGR tyrosine kinase inhibitors in lung adenocarcinoma—successes and challenges

Journal Article Journal of Thoracic Disease · June 1, 2022 Full text Cite

Harnessing the vulnerabilities of p53 mutants in lung cancer - Focusing on the proteasome: a new trick for an old foe?

Journal Article Cancer Biol Ther · April 2, 2020 Gain-of-function (GOF) p53 mutations occur commonly in human cancer and lead to both loss of p53 tumor suppressor function and acquisition of aggressive cancer phenotypes. The oncogenicity of GOF mutant p53 is highly related to its abnormal protein stabili ... Full text Link to item Cite

Abstracts from Women's Health 2019 June 28–30, 2019 Norfolk, VA

Journal Article Journal of Women's Health · June 2019 Full text Cite

Ketogenic Diet-Induced Severe Ketoacidosis in a Lactating Woman: A Case Report and Review of the Literature.

Journal Article Case Rep Nephrol · 2019 The ketogenic diet (KD) is a high-fat, adequate-protein, and low-carbohydrate diet that leads to nutritional ketosis and weight loss. It is known to induce ketosis but is not an established cause of clinically significant ketoacidosis. Lactation ketoacidos ... Full text Link to item Cite

Heparin: Past, Present, and Future.

Journal Article Pharmaceuticals (Basel) · July 4, 2016 Heparin, the most widely used anticoagulant drug in the world today, remains an animal-derived product with the attendant risks of adulteration and contamination. A contamination crisis in 2007-2008 increased the impetus to provide non-animal-derived sourc ... Full text Link to item Cite

Optimization of bioprocess conditions improves production of a CHO cell-derived, bioengineered heparin.

Journal Article Biotechnol J · July 2015 Heparin is the most widely used anticoagulant drug in the world today. Heparin is currently produced from animal tissues, primarily porcine intestines. A recent contamination crisis motivated development of a non-animal-derived source of this critical drug ... Full text Link to item Cite